Adverse drug events associated with disorders of coagulation

Critical Care Medicine

Volumn 38, Issue 6 SUPPL., 2010, Pages

  Barletta, Jeffrey F ^a   Cooper, Brad ^b   Ohlinger, Martin J ^c  

^a SPECTRUM HEALTH   (United States)

^b HAMOT MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Adverse drug event; Anticoagulation; Bleeding; Clotting; Critical illness; Heparin; Low molecular weight heparin; Prophylaxis; Reversal; Thrombolytic

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; CERTOPARIN; CONJUGATED ESTROGEN; DALTEPARIN; DESMOPRESSIN; DROTRECOGIN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEMOSTATIC AGENT; HEPARIN; HETASTARCH; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; STREPTOKINASE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UNINDEXED DRUG; UROKINASE; WARFARIN;

ABDOMINAL BLEEDING; ACUTE CORONARY SYNDROME; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; ANEMIA; ARTERY THROMBOSIS; BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; COMPRESSION THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DIABETES INSIPIDUS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; EPIDURAL HEMATOMA; FLUID RETENTION; FLUSHING; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART SURGERY; HEMODILUTION; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPONATREMIA; HYPOTENSION; INTENSIVE CARE UNIT; INTESTINE INFARCTION; LUNG EDEMA; LUNG EMBOLISM; MESENTERIC VEIN THROMBOSIS; MULTIPLE ORGAN FAILURE; MULTIPLE TRAUMA; NAUSEA; NEUROLOGIC DISEASE; NEUROSURGERY; NOCTURNAL ENURESIS; OFF LABEL DRUG USE; PATIENT SAFETY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PORTAL VEIN THROMBOSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SKIN BLEEDING; SOFT TISSUE DISEASE; SUBARACHNOID HEMORRHAGE; SURGICAL PATIENT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THORAX DISEASE; THROMBOEMBOLISM; THROMBOSIS; UROGENITAL TRACT DISEASE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; VON WILLEBRAND DISEASE;

EID: 77953113130     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de11f9     Document Type: Article

References (215)

1. Bates DW, Cullen DJ, Laird N, et al: Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274:29-34
2. Cullen DJ, Sweitzer BJ, Bates DW, et al: Preventable adverse drug events in hospitalized patients: A comparative study of intensive care and general care units. Crit Care Med 1997; 25:1289-1297
3. Kopp BJ, Erstad BL, Allen ME, et al: Medication errors and adverse drug events in an intensive care unit: Direct observation approach for detection. Crit Care Med 2006; 34:415-425
4. Leape LL, Brennan TA, Laird N, et al: The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324:377-384
5. Shojania KG, Duncan BW, McDonald KM, et al: Making Health Care Safer: A Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment, No. 43. July 2001. Rockville, MD. Agency for Healthcare Research and Quality. Available at http://www.ahrq.gov/clinic/ptsafety. Accessed September 10, 2009
6. Cohn SL: Prophylaxis of venous thromboembolism in the US: Improving hospital performance. J Thromb Haemost 2009; 7:1437-1445
7. Cook DJ, Crowther MA, Douketis J, et al: Research agenda: venous thromboembolism in medical-surgical critically ill patients. J Crit Care 2005; 20:330-333
8. Geerts WH, Bergqvist D, Pineo GF, et al: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 381S-453S
9. Ribic C, Lim W, Cook D, et al: Lowmolecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. J Crit Care 2009; 24:197-205
10. Fraisse F, Holzapfel L, Couland JM, et al: Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000; 161:1109-1114
11. Arnold DM, Donahoe L, Clarke FJ, et al: Bleeding during critical illness: A prospective cohort study using a new measurement tool. Clin Invest Med 2007; 30:E93-E102
12. Wein L, Wein S, Haas SJ, et al: Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: A meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167:1476-1486
13. Leonardi MJ, McGory ML, Ko CY: The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: A systematic review of 33 randomized controlled trials. Arch Surg 2006; 141:790-797; discussion, 797-799
14. Cook DJ, Rocker G, Meade M, et al: Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: A pilot study. J Crit Care 2005; 20:364-372
15. King CS, Holley AB, Jackson JL, et al: Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. Chest 2007; 131:507-516
16. Nutescu EA, Spinler SA, Wittkowsky A, et al: Low-molecular-weight heparins in renal impairment and obesity: Available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064-1083
17. Cohn SM, Moller BA, Feinstein AJ, et al: Prospective trial of low-molecular-weight heparin versus unfractionated heparin in moderately injured patients. Vasc Surg 1999; 33:219-223
18. Cothren CC, Smith WR, Moore EE, et al: Utility of once-daily dose of low-molecularweight heparin to prevent venous thromboembolism in multisystem trauma patients. World J Surg 2007; 31:98-104
19. Dennis JW, Menawat S, Von Thron J, et al: Efficacy of deep venous thrombosis prophylaxis in trauma patients and identification of high-risk groups. J Trauma 1993; 35: 132-138; discussion, 138-139
20. Geerts WH, Jay RM, Code KI, et al: A comparison of low-dose heparin with lowmolecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-707
21. Ginzburg E, Cohn SM, Lopez J, et al: Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. Br J Surg 2003; 90:1338-1344
22. Haentjens P: Thromboembolic prophylaxis in orthopaedic trauma patients: A comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium). Injury 1996; 27:385-390
23. Knudson MM, Collins JA, Goodman SB, et al: Thromboembolism following multiple trauma. J Trauma 1992; 32:2-11
24. Knudson MM, Morabito D, Paiement GD, et al.: Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma 1996; 41:446-459
25. Norwood SH, McAuley CE, Berne JD, et al: A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients. J Am Coll Surg 2001; 192:161-167
26. Shackford SR, Davis JW, HollingsworthFridlund P, et al: Venous thromboembolism in patients with major trauma. Am J Surg 1990; 159:365-369
27. Stannard JP, Lopez-Ben RR, Volgas DA, et al: Prophylaxis against deep-vein thrombosis following trauma: A prospective, randomized comparison of mechanical and pharmacologic prophylaxis. J Bone Joint Surg Am 2006; 88:261-266
28. Scales DC, Riva-Cambrin J, Le TL, et al: Prophylaxis against venous thromboembolism in neurointensive care patients: Survey of Canadian practice. J Crit Care 2009; 24: 176-184
29. Collen JF, Jackson JL, Shorr AF, et al: Prevention of venous thromboembolism in neurosurgery: A metaanalysis. Chest 2008; 134:237-249
30. Raabe A, Gerlach R, Zimmermann M, et al: The risk of haemorrhage associated with early postoperative heparin administration after intracranial surgery. Acta Neurochir (Wien) 2001; 143:1-7
31. Kim J, Gearhart MM, Zurick A, et al: Preliminary report on the safety of heparin for deep venous thrombosis prophylaxis after severe head injury. J Trauma 2002; 53: 38-42; discussion, 43
32. Kim KS, Brophy GM: Symptomatic venous thromboembolism: Incidence and risk factors in patients with spontaneous or traumatic intracranial hemorrhage. Neurocrit Care 2009; 11:28-33
33. Kleindienst A, Harvey HB, Mater E, et al: Early antithrombotic prophylaxis with low molecular weight heparin in neurosurgery. Acta Neurochir (Wien) 2003; 145: 1085-1090; discussion, 1090-1081
34. Kurtoglu M, Yanar H, Bilsel Y, et al: Venous thromboembolism prophylaxis after head and spinal trauma: Intermittent pneumatic compression devices versus low molecular weight heparin. World J Surg 2004; 28: 807-811
35. Norwood SH, McAuley CE, Berne JD, et al: Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. Arch Surg 2002; 137: 696-701; discussion, 701-702
36. Bates SM, Ginsberg JS: Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004; 351:268-277
37. Pastores SM: Management of venous thromboembolism in the intensive care unit. J Crit Care 2009; 24:185-191
38. Schulman S, Beyth RJ, Kearon C, et al: Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):257S-298S (Pubitemid 351892969)
39. Hirsh J, Bauer KA, Donati MB, et al: Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):141S-159S (Pubitemid 351892966)
40. Anand SS, Yusuf S, Pogue J, et al: Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003; 107: 2884-2888
41. van Dongen CJ, van den Belt AG, Prins MH, et al: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; 4:CD001100
42. Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med 2005; 353:1028-1040
43. Lubenow N, Eichler P, Lietz T, et al: Lepirudin in patients with heparin-induced thrombocytopenia Results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3:2428-2436
44. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999; 353: 429-438
45. Selleng K, Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35: 1165-1176
46. Warkentin TE, Greinacher A, Koster A, et al: Treatment and prevention of heparininduced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):340S-380S
47. Hursting MJ, Soffer J: Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf 2009; 32:203-218
48. Lewis BE, Wallis DE, Hursting MJ, et al: Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129:1407-1416
49. Keegan SP, Gallagher EM, Ernst NE, et al: Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother 2009; 43:19-27
50. Kiser TH, Jung R, MacLaren R, et al: Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005; 25:1736-1745
51. Smythe MA, Koerber JM, Forsyth LL, et al: Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy 2009; 29:1073-1081
52. Buller HR, Davidson BL, Decousus H, et al: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-873
53. Buller HR, Davidson BL, Decousus H, et al: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702
54. Mehta SR, Boden WE, Eikelboom JW, et al: Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with STand non-STsegment elevation acute coronary syndromes: An individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 2008; 118: 2038-2046
55. Gore JM, Granger CB, Simoons ML, et al: Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global use of strategies to open occluded coronary arteries. Circulation 1995; 92: 2811-2818
56. Kearon C, Kahn SR, Agnelli G, et al: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):454S-545S (Pubitemid 351892971)
57. ECC Committee S, Task Forces of the American Heart Association: 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112(24 Suppl):IV1-IV203
58. Adams HP Jr, del Zoppo G, Alberts MJ, et al: Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-1711
59. Albers GW, Amarenco P, Easton JD, et al: Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):630S-669S
60. Goodman SG, Menon V, Cannon CP, et al: Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):708S-775S
61. Wan S, Quinlan DJ, Agnelli G, et al: Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: A meta-analysis of the randomized controlled trials. Circulation 2004; 110:744-749
62. Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389
63. Fengler BT, Brady WJ: Fibrinolytic therapy in pulmonary embolism: An evidence-based treatment algorithm. Am J Emerg Med 2009; 27:84-95
64. Todd JL, Tapson VF: Thrombolytic therapy for acute pulmonary embolism: A critical appraisal. Chest 2009; 135:1321-1329
65. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
66. Levi M, Levy M, Williams MD, et al: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176: 483-490
67. Gentry CA, Gross KB, Sud B, et al: Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 2009; 37:19-25
68. Bertolini G, Rossi C, Anghileri A, et al: Use of Drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey. Intensive Care Med 2007; 33: 426-434
69. Kanji S, Perreault MM, Chant C, et al: Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: A Canadian multicenter observational study. Intensive Care Med 2007; 33:517-523
70. Wheeler A, Steingrub J, Schmidt GA, et al: A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. Crit Care Med 2008; 36:14-23
71. Levi M, Jonge E: Clinical relevance of the effects of plasma expanders on coagulation. Semin Thromb Hemost 2007; 33(8): 810-815
72. Westphal M, James MF, Kozek-Langenecker S, et al: Hydroxyethyl starches: Different products Different effects. Anesthesiology 2009; 111:187-202
73. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, et al: The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: A pooled analysis of randomized clinical trials. Anesth Analg 2008; 107:382-390
74. Weeks DL, Jahr JS, Lim JC, et al: Does Hextend impair coagulation compared to 6% hetastarch? An ex vivo thromboelastography study. Am J Ther 2008; 15:225-230
75. Dailey SE, Dysart CB, Langan DR, et al: An in vitro study comparing the effects of Hextend, Hespan, normal saline, and lactated Ringer's solution on thrombelastography and the activated partial thromboplastin time. J Cardiothorac Vasc Anesth 2005; 19: 358-361
76. Finfer S, Bellomo R, Boyce N, et al: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256 (Pubitemid 38669207)
77. Brunkhorst FM, Engel C, Bloos F, et al: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-139
78. NovoNordisk. NovoSeven Package Insert. Princeton, NJ, 2008
79. Broderick J, Connolly S, Feldmann E, et al: Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: A guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38: 2001-2023
80. Hedner U: Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008; 100:557-562
81. O'Connell KA, Wood JJ, Wise RP, et al: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298
82. Patanwala AE: Factor VIIa (recombinant) for acute traumatic hemorrhage. Am J Health Syst Pharm 2008; 65:1616-1623
83. Roberts HR, Monroe DM 3rd, Hoffman M: Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41(1 Suppl 1): 101-108
84. Voils S: Pharmacologic interventions for the management of critical bleeding. Pharmacotherapy 2007; 27:69S-84S
85. Barletta JF, Ahrens CL, Tyburski JG, et al: A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma 2005; 58:646-651
86. DiDomenico RJ, Massad MG, Kpodonu J, et al: Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest 2005; 127: 1828-1835
87. Thomas GO, Dutton RP, Hemlock B, et al: Thromboembolic complications associated with factor VIIa administration. J Trauma 2007; 62:564-569
88. Boffard KD, Riou B, Warren B, et al: Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59:8-15; discussion, 15-18
89. Mayer SA, Brun NC, Begtrup K, et al: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127-2137
90. Mayer SA, Brun NC, Begtrup K, et al: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-785
91. Mayer SA, Brun NC, Broderick J, et al: Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005; 36:74-79 (Pubitemid 40054178)
92. Mayer SA, Brun NC, Broderick J, et al: Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care 2006; 4:206-214
93. Aledort LM: Factor IX and thrombosis. Scand J Haematol Suppl 1977; 30:40-42
94. Kohler M: Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95(4 Suppl 1):S13-S17
95. Pindur G, Morsdorf S: The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. Thromb Res 1999; 95(4 Suppl 1):S57-S61
96. Bershad EM, Suarez JI: Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: A review of the literature. Neurocrit Care 2009 Dec 5 [Epub ahead of print]
97. Leissinger CA, Blatt PM, Hoots WK, et al: Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol 2008; 83:137-143
98. Levy JH, Tanaka KA, Dietrich W: Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109:918-926
99. Mannucci PM, Levi M: Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301-2311
100. Perkins JG, Cap AP, Weiss BM, et al: Massive transfusion and nonsurgical hemostatic agents. Crit Care Med 2008; 36(7 Suppl):S325-S339
101. Porte RJ, Leebeek FW: Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002; 62:2193-2211
102. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al: Perioperative blood transfusion and blood conservation in cardiac surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83(5 Suppl):S27-S86
103. Tinmouth AT, McIntyre LA, Fowler RA: Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients. CMAJ 2008; 178:49-57
104. Brown JR, Birkmeyer NJ, O'Connor GT: Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115:2801-2813
105. Fergusson DA, Hebert PC, Mazer CD, et al: A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-2331
106. Greilich PE, Jessen ME, Satyanarayana N, et al: The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: A randomized, double-blind, placebo-controlled, noninferiority trial. Anesth Analg 2009; 109:15-24
107. Henry D, Carless P, Fergusson D, et al: The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: A meta-analysis. CMAJ 2009; 180:183-193
108. Mangano DT, Miao Y, Vuylsteke A, et al: Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297:471-479
109. McIlroy DR, Myles PS, Phillips LE, et al: Antifibrinolytics in cardiac surgical patients receiving aspirin: A systematic review and meta-analysis. Br J Anaesth 2009; 102:168-178
110. Benoni G, Fredin H, Knebel R, et al: Blood conservation with tranexamic acid in total hip arthroplasty: A randomized, doubleblind study in 40 primary operations. Acta Orthop Scand 2001; 72:442-448
111. Coats T, Roberts I, Shakur H: Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2004; 4:CD004896
112. Dalmau A, Sabate A, Acosta F, et al: Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000; 91:29-34
113. Ekback G, Axelsson K, Ryttberg L, et al: Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000; 91:1124-1130
114. Hiippala ST, Strid LJ, Wennerstrand MI, et al: Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg 1997; 84:839-844
115. Jansen AJ, Andreica S, Claeys M, et al: Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth 1999; 83:596-601
116. Kang Y, Lewis JH, Navalgund A, et al: Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66:766-773
117. Kaspar M, Ramsay MA, Nguyen AT, et al: Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg 1997; 85:281-285
118. McMichan JC, Rosengarten DS, Philipp E: Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: A clinical study. Circ Shock 1982; 9:107-116
119. Miller RA, May MW, Hendry WF, et al: The prevention of secondary haemorrhage after prostatectomy: The value of antifibrinolytic therapy. Br J Urol 1980; 52:26-28
120. Mutter WP, Stillman IE, Dahl NK: Thrombotic microangiopathy and renal failure exacerbated by epsilon-aminocaproic acid. Am J Kidney Dis 2009; 53:346-350
121. Piriyawat P, Morgenstern LB, Yawn DH, et al: Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: A pilot study. Neurocrit Care 2004; 1:47-51
122. Tanaka N, Sakahashi H, Sato E, et al: Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J Bone Joint Surg Br 2001; 83:702-705
123. Veien M, Sorensen JV, Madsen F, et al: Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: A randomized, controlled study. Acta Anaesthesiol Scand 2002; 46:1206-1211
124. Clinical randomisation of an antifibrinolytic in significant haemorrhage. Available at: http://www.crash2.lshtm.ac.uk/MainFrame.htm. Accessed October 1, 2009
125. Sanofi-Aventis. DDAVP Package Insert. Bridgewater, NJ, 2007
126. Couch P, Stumpf JL: Management of uremic bleeding. Clin Pharm 1990; 9:673-681
127. Gralnick HR, McKeown LP, Williams SB, et al: Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988; 85:806-810
128. Donoghue MB, Latimer ME, Pillsbury HL, et al: Hyponatremic seizure in a child using desmopressin for nocturnal enuresis. Arch Pediatr Adolesc Med 1998; 152:290-292
129. Bond L, Bevan D: Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318:121
130. Byrnes JJ, Larcada A, Moake JL: Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28:63-65
131. Levi M, Cromheecke ME, de Jonge E, et al: Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet 1999; 354:1940-1947
132. Mannucci PM, Carlsson S, Harris AS: Desmopressin, surgery and thrombosis. Thromb Haemost 1994; 71:154-155
133. McLeod BC: Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990; 336:1137-1138
134. O'Brien JR, Green PJ, Salmon G, et al: Desmopressin and myocardial infarction. Lancet 1989; 333:664-665
135. Crescenzi G, Landoni G, Biondi-Zoccai G, et al: Desmopressin reduces transfusion needs after surgery: A meta-analysis of randomized clinical trials. Anesthesiology 2008; 109:1063-1076
136. Liu YK, Kosfeld RE, Marcum SG: Treatment of uraemic bleeding with conjugated oestrogen. Lancet 1984; 2:887-890
137. Boyd GL, Diethelm AG, Gelman S, et al: Correcting prolonged bleeding during renal transplantation with estrogen or plasma. Arch Surg 1996; 131:160-165
138. Bronner MH, Pate MB, Cunningham JT, et al: Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial. Ann Intern Med 1986; 105:371-374
139. Frenette L, Cox J, McArdle P, et al: Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. Anesth Analg 1998; 86:1183-1186
140. Heunisch C, Resnick DJ, Vitello JM, et al: Conjugated estrogens for the management of gastrointestinal bleeding secondary to uremia of acute renal failure. Pharmacotherapy 1998; 18:210-217
141. Livio M, Mannucci PM, Vigano G, et al: Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315:731-735
142. McCall RE, Bilderback KK: Use of intravenous Premarin to decrease postoperative blood loss after pediatric scoliosis surgery. Spine (Phila Pa 1976) 1997; 22:1394-1397
143. Shemin D, Elnour M, Amarantes B, et al: Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure. Am J Med 1990; 89:436-440
144. Hull RW, Hasbargen JA, Fall S, et al: Conjugated estrogens reduce endothelial prostacyclin production and fail to reduce postbypass blood loss. Chest 1991; 99:1116-1119
145. Ambrus JL, Schimert G, Lajos TZ, et al: Effect of antifibrinolytic agents and estrogens on blood loss and blood coagulation factors during open heart surgery. J Med 1971; 2:65-81
146. Boucher BA, Traub O: Achieving hemostasis in the surgical field. Pharmacotherapy 2009; 29:2S-7S
147. Kessler CM, Ortel TL: Recent developments in topical thrombins. Thromb Haemost 2009; 102:15-24
148. Lomax C, Traub O: Topical thrombins: Benefits and risks. Pharmacotherapy 2009; 29:8S-12S
149. Ofosu FA, Crean S, Reynolds MW: A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. Clin Ther 2009; 31:679-691
150. Carroll JF, Moskowitz KA, Edwards NM, et al: Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb Haemost 1996; 76:925-931
151. Chapman WC, Singla N, Genyk Y, et al: A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. JAm Coll Surg 2007; 205:256-265
152. Doria C, Fischer CP, Wood CG, et al: Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 2008; 24:785-794
153. Nelson PA, Powers JN, Estridge TD, et al: Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res 2001; 58:710-719
154. Ortel TL, Mercer MC, Thames EH, et al: Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233:88-96
155. Dorion RP, Hamati HF, Landis B, et al: Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998; 122: 887-894
156. Streiff MB, Ness PM: Acquired FV inhibitors: A needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42:18-26
157. Chouhan VD, De La Cadena RA, Nagaswami C, et al: Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: Effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997; 77:343-349
158. Christie RJ, Carrington L, Alving B: Postoperative bleeding induced by topical bovine thrombin: Report of two cases. Surgery 1997; 121:708-710
159. Ethicon Inc. Evithrom Package Insert. Somerville, NJ, 2007
160. Ortel TL, Charles LA, Keller FG, et al: Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45:128-135
161. Rapaport SI, Zivelin A, Minow RA, et al: Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992; 97:84-91
162. Zehnder JL, Leung LL: Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76:2011-2016
163. Zymo Genetics. Recothrom Package Insert. Seattle, WA, 2009
164. Singla NK, Ballard JL, Moneta G, et al: A phase 3b, open-label, single-group immunogenicity and safety study of topical re combinant thrombin in surgical hemostasis. J Am Coll Surg 2009; 209:68-74
165. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924
166. Phrommintikul A, Haas SJ, Elsik M, et al: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 2007; 369:381-388
167. Corwin HL, Gettinger A, Pearl RG, et al: Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288:2827-2835
168. Corwin HL, Gettinger A, Rodriguez RM, et al: Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27:2346-2350
169. Corwin HL, Gettinger A, Fabian TC, et al: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357:965-976
170. Corwin HL: Erythropoietin use in critically ill patients: Forest and trees. CMAJ 2007; 177:747-749
171. Tobu M, Iqbal O, Fareed D, et al: Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004; 10:225-232
172. Fuste B, Serradell M, Escolar G, et al: Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88:678-685
173. Crowther MA, Berry LR, Monagle PT, et al: Mechanisms responsible for the failure of protamine to inactivate low-molecularweight heparin. Br J Haematol 2002; 116:178-186
174. Young G, Yonekawa KE, Nakagawa PA, et al: Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007; 18:547-553
175. Bijsterveld NR, Moons AH, Boekholdt SM, et al: Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106:2550-2554
176. Sharathkumar AA, Crandall C, Lin JJ, et al: Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving
177. Sorensen B, Ingerslev J: A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 2006; 96:446-453
178. Ansell J, Hirsh J, Hylek E, et al: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6Suppl):160S-198S (Pubitemid 351892967)
179. Schulman S, Bijsterveld NR: Anticoagulants and their reversal. Transfus Med Rev 2007; 21:37-48
180. MacLaren R: Key concepts in the management of difficult hemorrhagic cases. Pharmacotherapy 2007; 27:93S-102S
181. Stein DM, Dutton RP, Kramer ME, et al: Recombinant factor VIIa: Decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. J Trauma 2008; 64:620-627; discussion, 627-628
182. Dager WE, King JH, Regalia RC, et al: Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006; 26:1091-1098
183. Sane DC, Califf RM, Topol EJ, et al: Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management. Ann Intern Med 1989; 111:1010-1022
184. Rabbat CG, Cook DJ, Crowther MA, et al: Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005; 20:357-363
185. Douketis J, Cook D, Meade M, et al: Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and pharmacodynamics: The DIRECT study. Arch Intern Med 2008; 168:1805-1812
186. Agnelli G, Piovella F, Buoncristiani P, et al: Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339:80-85
187. Cage TA, Lamborn KR, Ware ML, et al: Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas. J Neurooncol 2009; 93:151-156
188. Cerrato D, Ariano C, Fiacchino F: Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg 1978; 49:378-381
189. Constantini S, Kanner A, Friedman A, et al: Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: A prospective, randomized, double-blind study. J Neurosurg 2001; 94:918-921
190. Dickinson LD, Miller LD, Patel CP, et al: Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998; 43:1074-1081
191. Frim DM, Barker FG 2nd, Poletti CE, et al: Postoperative low-dose heparin decreases thromboembolic complications in neurosurgical patients. Neurosurgery 1992; 30: 830-832; discussion, 832-833
192. Gerlach R, Scheuer T, Beck J, et al: Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: Results of a prospective study. Neurosurgery 2003; 53:1028-1034; discussion, 1034-1035
193. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al: Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002; 122:1933-1937
194. Macdonald RL, Amidei C, Baron J, et al: Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol 2003; 59:363-372; discussion, 372-364
195. Macdonald RL, Amidei C, Lin G, et al: Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. Neurosurgery 1999; 45:245-251; discussion, 251-242
196. Nurmohamed MT, van Riel AM, Henkens CM, et al: Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75:233-238
197. Wen DY, Hall WA: Complications of subcutaneous low-dose heparin therapy in nonsurgical patients. Surg Neurol 1998; 50:521-525
198. The Urokinase Pulmonary Embolism Trial. A national cooperative study. Circulation 1973; 47(2 Suppl):II1-II108
199. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest 1990; 97:528-533
200. Dalla-Volta S, Palla A, Santolicandro A, et al: PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. JAm Coll Cardiol 1992; 20:520-526
201. Dotter CT, Seamon AJ, Rosch J, et al: Streptokinase and heparin in the treatment of pulmonary embolism: A randomized comparison. Vasc Surg 1979; 13:42-52
202. Goldhaber SZ, Haire WD, Feldstein ML, et al: Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341:507-511
203. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al: Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 1995; 2:227-229
204. Konstantinides S, Geibel A, Heusel G, et al: Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347:1143-1150
205. Levine M, Hirsh J, Weitz J, et al: A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98:1473-1479
206. Ly B, Arnesen H, Eie H, et al: A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203:465-470 (Pubitemid 8358211)
207. Marini C, DiRicco G, Rossi G, et al: Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: A randomized clinical trial. Respiration 1988; 54:162-173
208. Tibbutt DA, Davies JA, Anderson JA, et al: Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism. Br Med J 1974; 1:343-347
209. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
210. Vincent JL, Bernard GR, Beale R, et al: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33:2266-2277
211. Alten JA, Benner K, Green K, et al: Pediatric off-label use of recombinant factor VIIa. Pediatrics 2009; 123:1066-1072
212. Diprose P, Herbertson MJ, O'Shaughnessy D, et al: Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized doubleblind placebo-controlled pilot study. Br J Anaesth 2005; 95:596-602
213. Lodge JP, Jonas S, Oussoultzoglou E, et al: Recombinant coagulation factor VIIa in major liver resection: A randomized, placebocontrolled, double-blind clinical trial. Anesthesiology 2005; 102:269-275
214. Raobaikady R, Redman J, Ball JA, et al: Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: A double-blind, randomized, placebo-controlled trial. Br J Anaesth 2005; 94:586-591
215. Shao YF, Yang JM, Chau GY, et al: Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: A multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006; 191:245-249.